# Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)

> **NCT06401616** · PHASE4 · RECRUITING · sponsor: **Odense University Hospital** · enrollment: 1220 (estimated)

## Conditions studied

- Atrial Fibrillation
- Left Atrial Appendage Absent
- Anticoagulant Adverse Reaction

## Interventions

- **DRUG:** OAC will be discontinued for the duration of the trial

## Key facts

- **NCT ID:** NCT06401616
- **Lead sponsor:** Odense University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-21
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 1220 (ESTIMATED)
- **Last updated:** 2024-05-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06401616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06401616, "Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06401616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*